NCT05036850 (CKPTN) is a clinical trial in Kidney Diseases, sponsored by George (Beijing) Clinical Research Co. Ltd..

Who is sponsoring NCT05036850?

NCT05036850 is sponsored by George (Beijing) Clinical Research Co. Ltd..

What condition does NCT05036850 study?

NCT05036850 studies Kidney Diseases.

Is NCT05036850 still recruiting?

NCT05036850 is currently recruiting now. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT05036850: CKPTN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

China Kidney Patient Trials Network

Recruiting now Last updated 6 March 2023

What this trial tests

trial in Kidney Diseases in 1,200 participants. Currently enrolling.

Timeline

27 September 2021

Primary endpoint
15 September 2026

28 February 2031

Quick facts

Lead sponsor	George (Beijing) Clinical Research Co. Ltd.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,200
Start date	27 September 2021
Primary completion	15 September 2026
Estimated completion	28 February 2031
Sites	1 location across China

Conditions studied

Kidney Diseases — all drugs for Kidney Diseases →

Sponsor

George (Beijing) Clinical Research Co. Ltd.

Who can join

2 and older, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05036850 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by George (Beijing) Clinical Research Co. Ltd.
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing